Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Regains Compliance With Nasdaq Listing Requirement

NEW YORK — Chinese cancer molecular profiling firm Genetron Health said on Wednesday that it has regained compliance with the Nasdaq's $1 minimum bid price requirement.

In November, Genetron said that it was notified that the closing bid price of its American depositary shares (ADSs) was below the minimum of $1 per share for 30 consecutive business days, setting the stock up for delisting from the Nasdaq.

Genetron said that the Nasdaq has confirmed that the company's ADSs closed at $1 or greater for 10 consecutive business days, putting them back in compliance.

In early morning trading on Wednesday, Genetron's shares were up $.02 to $1.18.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.